Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 6 PART I, 1998, Pages 1871-1876

  Unco, Jaime R ^b   Jones, Denis ^b   Ashkin, David ^a   Hollender, Elena S ^b   Bernstein, David ^b   Albanese, Anthony P ^b   Pitchenik, Arthur E ^b  

^a A G Holley State Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG INDUCED DISEASE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER TOXICITY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HEPATITIS C; HEPATITIS, TOXIC; HIV SEROPOSITIVITY; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0031808038     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.6.9711039     Document Type: Article

References (42)

1. Cantwell, M. F., D. E. Snider, G. M. Cauthen, and I. Onorato. 1994. Epidemiology of tuberculosis in the United States, 1985 through 1992. J.A.M.A. 272:535-539.
2. Peters, B. S., E. Carlin, R. J. Weston, S. J. Loveless, J. Sweeney, J. Weber, and J. Main. 1994. Adverse effects of drugs used in the management of opportunistic infections associated with HIV Infection. Drug Saf. 10:439-454.
3. Kopanoff, D. E., D. E. Snider, and G. J. Caras. 1978. Isoniazid-related hepatitis: A U.S. Public Health Service Cooperative Surveillance Study. Am. Rev. Respir. Dis. 117:991-1001.
4. Bailey, W. C., S. L. Taylor, H. E. Dascomb, H. B. Greenberg, and M. M. Ziskind. 1973. Disturbed hepatic function during isoniazid chemoprophylaxis. Am. Rev. Respir. Dis. 529.
5. Gellis, S. N., and R. V. Murphy. Hapatitis following isoniazid. Dis. Chest. 28:462.
6. Gronhagen-Riska, C., P. E. Hellst, B. Froseth. 1978. Pisposing factors in hepatitis induced by azid-rifampin treatment of tuberculosis. Am. Rev. Respir. Dis. 118:461-466.
7. Durand, D. Pessayre, M. Fournier, J. Belghiti, S. Erlinger, and J. Bernuau. 1995. Antituberculous therapy and acute liver failure (letter). Lancet 345:1070-1072.
8. Van der Kooi, K., J. J. Mottet, and C. Regamey. 1994. Isniazid is not always the cause of hepatitis during the treatment of tuberculosis (letter). Clin. Infect Dis. 19:98.
9. Stevens, C. E., P. E. Taylor, Q. L. Choo, D. W. Bradley, G. Kuo, and M. Houghlon. 1990. Epidemiology of hepatitis C virus: a preliminary study in volunteer blood donors. J.A.M.A. 263:49-53.
10. Alter, M. J. 1994. Transmission of hepatitis C virus: route, dose and titser. N. Engl. J. Med. 330:784.
11. National Institutes of Health Consensus Conference on Management of Hepatitis C. Bethesda, MD, March 22-24, 1997. NIH statement. U.S. Government Printing Office, Bethesda, MD.
12. Carithers, Jr. R. L., and S. S. Emerson. 1997. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26:83S-88S.
13. Durand, F., J. Bernuau, D. Pessayre, D. Samuel, J. Belaiche, C. Deggott, H. Bismuth, J. Belghiti, S. Ehrlinger, B. Rueff, and J. P. Benhamou. 1995. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 21:929-932.
14. Turktas, H., M. Unsal, N. Tulek, and O. Oruc. 1994. Hepatotoxicity of antituberculous therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis? Tuber. Lung Dis. 75:58-60.
15. Centers For Disease Control/American Thoracic Society. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
16. Steele, M. A., R. F. Burk, and R. M. DesPrez. 1991. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 99:465-471.
17. Mitchell, I., J. Wendon, S. Fitt, and R. Williams. 1995. Anti-tuberculous therapy and acute liver failure. Lancet 345:555-556.
18. Peters, M. 1996. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 23:909-914.
19. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. 1994. American Psychiatric Association, Washington, DC.
20. Lindsay, K. L., G. L. Davis, and E. R. Schiff. 1996. Response to higher doses of interferon alpha-2b in patients with chronic hepatitis C: a randomized multicenter trial. The Hepatitis Interventional Group. Hepatology 24:1034-1040.
21. Harding, S. M., and W. C. Bailey. 1994. Chemotherapy of tuberculosis. In D. Scholssberg, editor. Tuberculosis, 3rd ed. Springer-Verlag, New York. 69-88.
22. Parasarthy, R., G. Raghupati Sarma, B. Janardhanam, P. Ramachandran, T. Santha, S. Siuasubramanian, P. R. Somasundaram, and S. P. Tripathy. 1986. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short course regiments containing isoniazid, rifampin and pyrazinamide. Tubercle 67:99-108.
23. Turner, M., and R. Haskal. 1995. Drug-induced hepatotoxicity in an inpatient TB unit: Lemuel Shattuck Hospital (abstract). Am. J. Respir. Dis. Crit. Care Med. 151:A514.
24. Dawson, G. J., R. R. Lesniewski, J. L. Stewart, K. M. Boardway, R. A. Gutierrez, L. Pendy, R. G. Johnson, X. Alcalde, K. U. Rote, S. G. Devare, W. G. Robey, and D. A. Peterson. 1991. Detection of antibodies to hepatitis C virus in US blood donors. J. Clin. Microbiol. 29:551-556.
25. Ozick, L. A., L. Jacob, G. M. Comer, T. P. Lee, J. Ben-Zvi, S. S. Donnelson, and C. P. Felton. 1995. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am. J. Gastroenterol. 90:1978-1982.
26. Ungo, J. R., D. Ashkin, E. S. Hollender, S. D. Ryan, D. Bernstein, A. P. Albanese, and A. E. Pitchenik. 1996. Antituberculosis drug-induced hepatotoxicity (ATDIH): the possible role of hepatitis viruses (abstract). Am. J. Respir. Crit. Care Med. 153:A410.
27. Alter, H. J., H. S. Margolis, K. Krawczynski, A. Maras, F. N. Judson, P. Y. Hu, W. J. Alexander, R. E. Sampliner, M. A. Gerber, G. Kuo, M. Houghton, and D. W. Bradley. 1989. Clinical outcome and risk factors associated with hepatitis C in the United States. Hepatology 10:581.
28. Moyle, G. L., and S. E. Barton. 1995. HIV-protease inhibitors in the management of HIV-infection. J. Antsimicrob. Chemother. 38:921-925.
29. McGregor, M. M., P. Olliaro, and L. Wolmarans. 1996. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 154:1462-1467.
30. Scheuer, P. J., P. Ashrafzadel, S. Sherlock, D. Brown, and G. M. Dushienko. 1992. The pathology of hepatitis C. Hepatology 15:567-571.
31. Gerber, M. A. 1997. Histopathology of hepatitis C virus infection. Clin. Liver Dis. 1:529-541.
32. Goodman and Oilman's: The Pharmacological Basis of Therapeutics. 1995. 8th ed. Macmillan, New York. 1211-1223.
33. Baron, S., S. Tyring, W. R. Fleischmann, D. H. Coppenhauer, D. W. Niesel, G. R. Kumpel, G. J. Stanton, and T. K. Hughes. 1991. The interferons: mechanism of action and clinical application. J.A.M.A. 266: 1375-1383.
34. Aizawa, Y., M. Zeniya, H. Takahashi, and G. Toda. 1996. Pattern of immune responses and the efficacy of IFN therapy in chronic hepatitis type C. Prog. Hepatol. 2:39-53.
35. Blatt, L. M., J. M. Davis, S. B. Klein, and M. W. Taylor. 1996. The bio-logic activity and molecular characterization of a novel synthetic alpha interferon species: Consensus Interferon. J. Interferon Cytokine Res. 76:489-499.
36. Weinstock-Guttman, B., R. M. Ransohoff, R. P. Kinkel, and R. A. Rudick. 1995. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neural. 37:7-15.
37. Reiter, Z. 1993. Interferon: a major regulator on natural killer cell-mediated cytotoxicity. J. Interferon Res. 13:247-257.
38. Fried, M. W., and J. H. Hoofnagle. 1995. Therapy of hepatitis C. Semin. Liver Dis. 15:82-91.
39. 2 production by cultured liver biopsy in patients with chronic viral hepatitis; can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J. Hepatol. 19:228-231.
40. Rothfield, N. F., W. F. Bierer, and J. W. Garfield. 1978. Isoniazid induction of antinuclear antibodies. Ann. Intern. Med. 88:650-652.
41. Graber, C. D., J. Jebaily, R. L. Galphin, and E. Doering. 1973. Light chain proteinuria and humoral immunocompetence in tuberculosis patients treated with rifampin. Am. Rev. Respir. Dis. 107:713-717.
42. Gupta, S., M. H. Greco, and I. Siegel. 1975. Suppression of T-lymphocyte rosettes by rifampin. Ann. Intern. Med. 82:484-488.